SIC 2834 – Pharmaceutical Preparations
Valuation | |
---|---|
Market Cap ($M) | 25.19 |
Enterprise Value ($M) | 25.19 |
Book Value ($M) | 0.00 |
Book Value / Share | 0.00 |
Price / Book | n/a |
NCAV ($M) | 0.00 |
NCAV / Share | 0.00 |
Price / NCAV | n/a |
Profitability (mra) | |
---|---|
Return on Invested Capital (ROIC) | n/a |
Return on Assets (ROA) | 0.00 |
Return on Equity (ROE) | n/a |
Liquidity (mrq) | |
---|---|
Quick Ratio | n/a |
Current Ratio | n/a |
Balance Sheet (mrq) ($M) | |
---|---|
Current Assets | 0.00 |
Assets | 0.00 |
Liabilities | 0.00 |
Debt | n/a |
Equity | n/a |
Income Statement (mra) ($M) | |
---|---|
Revenue | 0.00 |
Operating Income | 0.00 |
Net Income | 0.00 |
Cash Flow Statement (mra) ($M) | |
---|---|
Cash From Operations | 0.00 |
Cash from Investing | 0.00 |
Cash from Financing | 0.00 |
(click for more detail) |
File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
---|---|---|---|---|
13G | Ayrton Capital LLC | 9.90 | ||
13G/A | Boothbay Fund Management, Llc | 0.00 | ||
13G/A | Atw Spac Management Llc | 0.00 | ||
13G/A | Polar Asset Management Partners Inc. | 7.70 | ||
13G/A | Weiss Asset Management LP | 0.00 |
Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
---|---|---|---|---|
(click for more detail) |
Date | Insider Trades | Code | Shares | Value |
---|---|---|---|---|
(click for more detail) |
Short Volume | |||
---|---|---|---|
Market Date | Short Volume | Total Volume | Short Volume Ratio |
2,982 | 16,576 | 17.99 | |
13,676 | 50,157 | 27.27 | |
183 | 22,154 | 0.83 | |
13,260 | 43,098 | 30.77 | |
(click for more detail) |
Similar Companies | |
---|---|
NRSN – NeuroSense Therapeutics Ltd. | NRXP – NRx Pharmaceuticals, Inc. |
NVCT – Nuvectis Pharma, Inc. | OCGN – Ocugen, Inc. |
OCX – OncoCyte Corporation |
Financial data and stock pages provided by
Fintel.io